1. Immunology/Inflammation
  2. MyD88

ST 2825 

Cat. No.: HY-50937 Purity: 99.51%
Handling Instructions

ST 2825 is a MyD88 homodimerization inhibitor.

For research use only. We do not sell to patients.

ST 2825 Chemical Structure

ST 2825 Chemical Structure

CAS No. : 894787-30-5

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 1905 In-stock
Stock in the United States
Estimated Time of Arrival: December 31
1 mg USD 426 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
5 mg USD 1464 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
10 mg USD 2227 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

    ST 2825 purchased from MCE. Usage Cited in: Mol Med Rep. 2015 Jul;12(1):895-904.

    The degradation of IκBα and nuclear translocation of p65 induced by IL-1β are also dramatically blocked by pretreatment of the cells with TLR2Ab, ST2825 and TPCA-1. The cultured leukocytes are obtained from a normal control mouse and stimulated with IL-1β (10 ng/ml) for 1 h with or without pre-treatment of BML-111 (1 mM) for 30 min, BOC1 (100 μM) for 30 min, TLR2Ab (1 μg/mL) for 1 h, goat IgG (1 μg/mL) for 1 h, ST2825 (20 μM) for 1 h or TPCA-1 (10 μM) for 1 h. The western blot is representative

    ST 2825 purchased from MCE. Usage Cited in: Genet Mol Res. 2016 Mar 4;15(1):15016826.

    Effect of ST2825 on IκB, cyclin D1, cleaved caspase-3, and bcl-2 expression in HepG-2 cells as determined by western blot analysis (lane 1, blank; lane 2, control; and lane 3, high-dose ST2825). Compared with the control, 24 h of ST2825 treatment significantly inhibits cyclin D1 and bcl-2 expression (P>0.05), but 24-h treatment with ST2825 significantly increases cleaved caspase-3 expression (P<0.05) in the high-dose group.

    ST 2825 purchased from MCE. Usage Cited in: Brain Res. 2016 Jul 15;1643:130-9.

    Effect of ST2825 treatment on the expression of MyD88 at 24h after TBI. Levels of MyD88 are significantly increased at 24 h after TBI. ST2825 (20 μg/μL) treatment reduces the levels of MyD88 at 24 h post TBI. No difference is detected between the TBI group and TBI+vehicle group.

    ST 2825 purchased from MCE. Usage Cited in: Exp Neurol. 2017 May 18;295:23-35.

    Western blotting analysis of the Tyr1472-phosphorylation of the NR2B subunit in the hippocampus of experimental rats under the various treatment conditions. All rats are killed 90 min after Pilocarpine injection. IL-1β (1 ng in 2 μL) is injected 10 min before Pilocarpine. ST2825 (10 μg in 2 μL) is injected 20 min before Pilocarpine. Representative Western blotting bands corresponding to the specific proteins and the various pharmacological treatments.

    ST 2825 purchased from MCE. Usage Cited in: Anticancer Res. 2017 Nov;37(11):6203-6209.

    Effect of ST2825 on the expression of myeloid differentiation primary response gene 88 (MYD88) and nuclear factor kappa B (NF-ĸB) signaling proteins. Cells are cultured with 100 μM ST2825 for 6 h and analysed for protein expression by immunoblotting. DMSO is used as a vehicle control and α-tubulin as a loading control.

    ST 2825 purchased from MCE. Usage Cited in: Sci Rep. 2017 Nov 17;7(1):15797.

    Representative Western blot to show the level of MyD88 protein. The upper panel shows representative protein levels of MyD88. Tubulin is detected as a loading control. The bottom panel shows quantitative data of MyD88.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References


    ST 2825 is a MyD88 homodimerization inhibitor.

    IC50 & Target


    In Vitro

    ST2825 blocks IL-1R/TLR signaling by interfering with MyD88 homodimerization. ST2825 inhibits this interaction in a concentration-dependent manner with ~40% inhibition of dimerization at 5 μM ST2825 and 80% inhibition at 10 μM ST2825[1].

    In Vivo

    ST2825 dose-dependently inhibits IL-1β-induced production of IL-6 in treated mice after oral administration. The animals are administered orally with the appropriate vehicles or ST2825 at doses ranging from 50 to 200 mg/kg, 5 min prior to i.p. injection with 20 μg/kg IL-1β. ST2825 exertes a significant inhibition of IL-1β-stimulated production of IL-6 at 100 and 200 mg/kg[1].

    Preparing Stock Solutions
    Concentration Volume Mass 1 mg 5 mg 10 mg
    1 mM 1.6906 mL 8.4529 mL 16.9059 mL
    5 mM 0.3381 mL 1.6906 mL 3.3812 mL
    10 mM 0.1691 mL 0.8453 mL 1.6906 mL
    Please refer to the solubility information to select the appropriate solvent.
    Cell Assay

    ST2825 is dissolved in DMSO and stored, and then diluted with appropriate media (DMSO 0.1%) before use[1].

    HeLa cells are seeded at 105 cells/mL in a 96-well tissue-culture plate. After incubating overnight, the medium is discarded, and the cells are added with tissue culture medium, 10% FBS, containing ST2825 at concentrations ranging from 0.1 to 10 μM and DMSO at 0.1% final concentration. The cells are incubated for 6 and 18 h and then added with the yellow XTT (0.3 mg/mL) for further 2 h of incubation. At the end of the incubation periods, reactions are quantified by using a Sirio S Seac microplate reader[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration

    ST2825 is administered orally as 0.5% suspension in carboxymethylcellulose (CMC)[1].

    Mice (female C57Bl/6) are divided into experimental groups of 15 mice. They are injected i.p. with saline (control animals) or recombinant murine IL-1β (20 μg/kg). A time-course analysis of IL-6 production established that the peak of cytokine is reached 2 h after IL-1β injection. ST2825, administered orally as 0.5% suspension in carboxymethylcellulose (CMC) or CMC alone, is supplied to the experimental mice groups. Two hours after IL-1β injection, the animals are killed, and sera are collected to assay IL-6 levels. Mice, which are treated orally with 100 and 200 mg/kg ST2825, shows lower levels of IL-6 versus CMC-treated mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Molecular Weight




    CAS No.



    O=C(N([[email protected]]1C(N)=O)[[email protected]@](SCC1)([H])C2)[[email protected]]2(CCC3)N3C(CC4=CC=C(C=C4)NC(COC(C(Cl)=C5)=CC=C5Cl)=O)=O

    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    10 mM in DMSO

    ST 2825 is dissolved in DMSO. ST2825 solution (0.5 μL) is administered via intracerebroventricular(ICV) injection at 15 min post-injury, using a 1 μL Hamilton microsyringe[4].
    ST 2825 is dissolved in 10% DMSO in 0.1 M PBS[5].
    ST 2825 is first reconstituted in 100% DMSO, followed by dilution to a working amount (5 mg/kg/200 uL in 0.1% DMSO in PBS)[6].

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.


    Purity: 99.51%

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name



    Applicant name *


    Email address *

    Phone number *


    Organization name *

    Country or Region *


    Requested quantity *


    Bulk Inquiry

    Inquiry Information

    Product Name:
    ST 2825
    Cat. No.: